First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

BACKGROUND: GWN323 is an IgG1 monoclonal antibody (mAb) against the glucocorticoid-induced tumor necrosis factor receptor-related protein. This first-in-human, open-label phase I/Ib study aimed to investigate the safety and tolerability and to identify the recommended doses of GWN323 with/without sp...

Descripción completa

Detalles Bibliográficos
Autores principales: Piha-Paul, Sarina A, Geva, Ravit, Tan, Tira J, Lim, Darren WT, Hierro, Cinta, Doi, Toshikiko, Rahma, Osama, Lesokhin, Alexander, Luke, Jason John, Otero, Javier, Nardi, Lisa, Singh, Angad, Xyrafas, Alexandros, Chen, Xinhui, Mataraza, Jennifer, Bedard, Philippe L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365809/
https://www.ncbi.nlm.nih.gov/pubmed/34389618
http://dx.doi.org/10.1136/jitc-2021-002863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365809/
https://www.ncbi.nlm.nih.gov/pubmed/34389618
http://dx.doi.org/10.1136/jitc-2021-002863

Ejemplares similares